Given the effect of targeting CSB in these p53 and MMR-deficient prostate cancer cell lines, an isogenic series of cell lines derived from HCT116 colorectal cancer cells were used to better assess the impact of p53- and MMR-deficiency under conditions in which CSB is silenced by RNAi. The gene discussed is MRC1; the disease is prostate carcinoma.